Abstract
Statins are recommended for first-line management of elevated cholesterol in the primary and secondary prevention of atherosclerotic cardiovascular disease. Statins may occasionally be associated with mild transaminase elevations but can also result in life-threatening liver injury. Atorvastatin is the most common cause of clinically significant liver injury in this drug class. We report a case of severe, asymptomatic liver injury in a hepatocellular pattern in a 71-year-old man occurring within 3 months of switching from simvastatin to high-intensity atorvastatin therapy. Hepatitis improved rapidly with cessation of atorvastatin and did not recur after resuming simvastatin.
Original language | English (US) |
---|---|
Journal | Journal of Investigative Medicine High Impact Case Reports |
Volume | 9 |
DOIs | |
State | Published - 2021 |
Keywords
- atorvastatin
- drug-induced liver injury
- hepatocellular injury
- simvastatin
- statins
- transaminitis
ASJC Scopus subject areas
- Epidemiology
- Safety, Risk, Reliability and Quality
- Safety Research